Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? (original) (raw)

• Moffett, J. R. & Namboodiri, M. A. Tryptophan and the immune response. Immunol. Cell Biol. 81, 247–265 (2003).
  CAS PubMed Google Scholar
• Pfefferkorn, E. R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl Acad. Sci. USA 81, 908–912 (1984).
  CAS PubMed PubMed Central Google Scholar
• Yoshida, R. & Hayaishi, O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc. Natl Acad. Sci. USA 75, 3998–4000 (1978).
  CAS PubMed PubMed Central Google Scholar
• Yoshida, R., Urade, Y., Tokuda, M. & Hayaishi, O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc. Natl Acad. Sci. USA 76, 4084–4086 (1979).
  CAS PubMed PubMed Central Google Scholar
• Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191–1193 (1998).
  CAS PubMed Google Scholar
• Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263–274 (2005).
  CAS Google Scholar
• Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363–1372 (1999).
  CAS PubMed PubMed Central Google Scholar
• Lee, G. K. et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107, 452–460 (2002).
  CAS PubMed PubMed Central Google Scholar
• Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633–642 (2005).
  CAS PubMed Google Scholar
• Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459–468 (2002).
  CAS PubMed PubMed Central Google Scholar
• Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447–457 (2002).
  CAS PubMed PubMed Central Google Scholar
• Fallarino, F. et al. T cell apoptosis by kynurenines. Adv. Exp. Med. Biol. 527, 183–190 (2003).
  CAS PubMed Google Scholar
• Chen, W., Liang, X., Peterson, A. J., Munn, D. H. & Blazar, B. R. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181, 5396–5404 (2008).
  CAS PubMed Google Scholar
• Hayashi, T. et al. 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc. Natl Acad. Sci. USA 104, 18619–18624 (2007).
  CAS PubMed PubMed Central Google Scholar
• Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9, 1269–1274 (2003).
  CAS PubMed Google Scholar
• Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Med. 11, 312–319 (2005).
  CAS PubMed Google Scholar
• Prendergast, G. C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27, 3889–3900 (2008).
  CAS PubMed Google Scholar
• Chang, M. Y. et al. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res. 67, 100–107 (2007).
  CAS PubMed Google Scholar
• Ge, K. et al. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int. J. Cancer 85, 376–383 (2000).
  CAS PubMed Google Scholar
• Ge, K. et al. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int. J. Cancer 86, 155–161 (2000).
  CAS PubMed Google Scholar
• Chang, M. Y. et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 67, 7605–7612 (2007).
  CAS PubMed Google Scholar
• Tajiri, T. et al. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin. Cancer Res. 9, 3345–3355 (2003).
  CAS PubMed Google Scholar
• Ge, K. et al. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl Acad. Sci. USA 96, 9689–9694 (1999).
  CAS PubMed PubMed Central Google Scholar
• Baban, B. et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 17, 909–919 (2005).
  CAS PubMed Google Scholar
• Fallarino, F. et al. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int. Immunol. 17, 1429–1438 (2005).
  CAS PubMed Google Scholar
• Mellor, A. L. et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171, 1652–1655 (2003).
  CAS PubMed Google Scholar
• Munn, D. H. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867–1870 (2002).
  CAS PubMed Google Scholar
• Terness, P., Chuang, J. J., Bauer, T., Jiga, L. & Opelz, G. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood 105, 2480–2486 (2005).
  CAS PubMed Google Scholar
• Terness, P., Chuang, J. J. & Opelz, G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol. 27, 68–73 (2006).
  CAS PubMed Google Scholar
• Löb, S. et al. Are indoleamine-2,3-dioxygenase producing human dendritic cells a tool for suppression of allogeneic T-cell responses? Transplantation 83, 468–473 (2007).
  PubMed Google Scholar
• Lee, J. R. et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83, 1457–1466 (2003).
  CAS PubMed Google Scholar
• Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280–290 (2004).
  CAS PubMed PubMed Central Google Scholar
• Löb, S. et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58, 153–157 (2009).
  PubMed Google Scholar
• Brandacher, G. et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12, 1144–1151 (2006).
  CAS PubMed Google Scholar
• Pan, K. et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 134, 1247–1253 (2008).
  CAS PubMed Google Scholar
• Ishio, T. et al. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 19, 319–326 (2004).
  CAS PubMed Google Scholar
• Riesenberg, R. et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res. 13, 6993–7002 (2007).
  CAS PubMed Google Scholar
• Brandacher, G., Winkler, C., Schroecksnadel, K., Margreiter, R. & Fuchs, D. Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients. Curr. Drug Metab. 7, 599–612 (2006).
  CAS PubMed Google Scholar
• Melichar, B., Solichova, D. & Freedman, R. S. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int. J. Gynecol. Cancer 16, 240–252 (2006).
  CAS PubMed Google Scholar
• Murr, C. et al. Neopterin as a prognostic parameter in patients with squamous-cell carcinomas of the oral cavity. Int. J. Cancer 79, 476–480 (1998).
  CAS PubMed Google Scholar
• Murr, C. et al. Neopterin is an independent prognostic variable in females with breast cancer. Clin. Chem. 45, 1998–2004 (1999).
  CAS PubMed Google Scholar
• Murr, C. et al. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res. 19, 1721–1728 (1999).
  CAS PubMed Google Scholar
• Prommegger, R. et al. Neopterin: a prognostic variable in operations for lung cancer. Ann. Thorac Surg. 70, 1861–1864 (2000).
  CAS PubMed Google Scholar
• Weinlich, G., Murr, C., Richardsen, L., Winkler, C. & Fuchs, D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214, 8–14 (2007).
  PubMed Google Scholar
• Farrar, M. A. & Schreiber, R. D. The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol. 11, 571–611 (1993).
  CAS PubMed Google Scholar
• Ozaki, Y., Edelstein, M. P. & Duch, D. S. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc. Natl Acad. Sci. USA 85, 1242–1246 (1988).
  CAS PubMed PubMed Central Google Scholar
• Takikawa, O., Kuroiwa, T., Yamazaki, F. & Kido, R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 263, 2041–2048 (1988).
  CAS PubMed Google Scholar
• Yoshida, R., Park, S. W., Yasui, H. & Takikawa, O. Tryptophan degradation in transplanted tumor cells undergoing rejection. J. Immunol. 141, 2819–2823 (1988).
  CAS PubMed Google Scholar
• Yu, W. G. et al. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int. Immunol. 8, 855–865 (1996).
  CAS PubMed Google Scholar
• Brunda, M. J. et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223–1230 (1993).
  CAS PubMed Google Scholar
• Nastala, C. L. et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153, 1697–1706 (1994).
  CAS PubMed Google Scholar
• Zou, J. P. et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7, 1135–1145 (1995).
  CAS PubMed Google Scholar
• Friberg, M. et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 101, 151–155 (2002).
  CAS PubMed Google Scholar
• Hou, D. Y. et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67, 792–801 (2007).
  CAS PubMed Google Scholar
• Windbichler, G. H. et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82, 1138–1144 (2000).
  CAS PubMed PubMed Central Google Scholar
• Giannopoulos, A. et al. The immunomodulating effect of interferon-γ intravesical instillations in preventing bladder cancer recurrence. Clin. Cancer Res. 9, 5550–5558 (2003).
  CAS PubMed Google Scholar
• Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745 (2000).
  CAS PubMed Google Scholar
• Takeshita, F. et al. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167, 3555–3558 (2001).
  CAS PubMed Google Scholar
• Speiser, D. E. et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739–746 (2005).
  CAS PubMed PubMed Central Google Scholar
• Mellor, A. L. et al. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 175, 5601–5605 (2005).
  CAS PubMed Google Scholar
• Wingender, G. et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36, 12–20 (2006).
  CAS PubMed Google Scholar
• Fallarino, F. & Puccetti, P. Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. Eur. J. Immunol. 36, 8–11 (2006).
  CAS PubMed Google Scholar
• Choi, B. K., Asai, T., Vinay, D. S., Kim, Y. H. & Kwon, B. S. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 34, 233–242 (2006).
  CAS PubMed Google Scholar
• Mittler, R. S. et al. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol. Res. 29, 197–208 (2004).
  CAS PubMed Google Scholar
• Seo, S. K. et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nature Med. 10, 1088–1094 (2004).
  CAS PubMed Google Scholar
• Kim, J. A. et al. Divergent effects of 4–1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res. 61, 2031–2037 (2001).
  CAS PubMed Google Scholar
• May, K. F. Jr., Chen, L., Zheng, P. & Liu, Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62, 3459–3465 (2002).
  CAS PubMed Google Scholar
• Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S. & Chen, L. NK1.1 cells express 4–1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190, 167–172 (1998).
  CAS PubMed Google Scholar
• Melero, I. et al. Monoclonal antibodies against the 4–1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682–685 (1997).
  CAS PubMed Google Scholar
• Nam, K. O., Kang, W. J., Kwon, B. S., Kim, S. J. & Lee, H. W. The therapeutic potential of 4–1BB (CD137) in cancer. Curr. Cancer Drug Targets 5, 357–363 (2005).
  CAS PubMed Google Scholar
• Baban, B. et al. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61, 67–77 (2004).
  CAS PubMed Google Scholar
• Knox, W. E. & Mehler, A. H. The conversion of tryptophan to kynurenine in liver. I. The coupled tryptophan peroxidase-oxidase system forming formylkynurenine. J. Biol. Chem. 187, 419–430 (1950).
  CAS PubMed Google Scholar
• Minatogawa, Y., Suzuki, S., Ando, Y., Tone, S. & Takikawa, O. Tryptophan pyrrole ring cleavage enzymes in placenta. Adv. Exp. Med. Biol. 527, 425–434 (2003).
  CAS PubMed Google Scholar
• Tatsumi, K. et al. Induction of tryptophan 2,3-dioxygenase in the mouse endometrium during implantation. Biochem. Biophys. Res. Commun. 274, 166–170 (2000).
  CAS PubMed Google Scholar
• Suzuki, S. et al. Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti. Biochem. J. 355, 425–429 (2001).
  CAS PubMed PubMed Central Google Scholar
• Britan, A., Maffre, V., Tone, S. & Drevet, J. R. Quantitative and spatial differences in the expression of tryptophan-metabolizing enzymes in mouse epididymis. Cell Tissue Res. 324, 301–310 (2006).
  CAS PubMed Google Scholar
• Haber, R., Bessette, D., Hulihan-Giblin, B., Durcan, M. J. & Goldman, D. Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J. Neurochem. 60, 1159–1162 (1993).
  CAS PubMed Google Scholar
• Yamamoto, S. & Hayaishi, O. Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes. J. Biol. Chem. 242, 5260–5266 (1967).
  CAS PubMed Google Scholar
• Yoshida, R. et al. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. Arch. Biochem. Biophys. 203, 343–351 (1980).
  CAS PubMed Google Scholar
• Yuasa, H. J. et al. Evolution of vertebrate indoleamine 2,3-dioxygenases. J. Mol. Evol. 65, 705–714 (2007).
  CAS PubMed Google Scholar
• Yamane, T., Miller, D. L. & Hopfield, J. J. Discrimination between D- and L-tyrosyl transfer ribonucleic acids in peptide chain elongation. Biochemistry 20, 7059–7064 (1981).
  CAS PubMed Google Scholar
• Cady, S. G. & Sono, M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291, 326–333 (1991).
  CAS PubMed Google Scholar
• Peterson, A. C. et al. Evaluation of functionalized tryptophan derivates and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase. Med. Chem. Res. 3, 531–544 (1994).
  CAS Google Scholar
• Metz, R. et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67, 7082–7087 (2007).
  CAS PubMed Google Scholar
• Ball, H. J. et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396, 203–213 (2007).
  CAS PubMed Google Scholar
• Lob, S. et al. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111, 2152–2154 (2008).
  CAS PubMed Google Scholar
• Katz, J. B., Muller, A. J. & Prendergast, G. C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222, 206–221 (2008).
  CAS PubMed Google Scholar
• Agaugue, S., Perrin-Cocon, L., Coutant, F., Andre, P. & Lotteau, V. 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol. 177, 2061–2071 (2006).
  CAS PubMed Google Scholar
• Steinman, R. M. & Banchereau, J. Taking dendritic cells into medicine. Nature 449, 419–426 (2007).
  CAS PubMed Google Scholar
• Kudo, Y. & Boyd, C. A. Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles. J. Physiol. 531, 405–416 (2001).
  CAS PubMed PubMed Central Google Scholar
• Curti, A. et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells. Blood 109, 2871–2877 (2007).
  CAS PubMed Google Scholar
• Okamoto, T. et al. Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue: Down-regulation of the indoleamine 2,3-dioxygenase (IDO) transcription by tryptophan and its analogue. Cytotechnology 54, 107–113 (2007).
  CAS PubMed PubMed Central Google Scholar
• Alvarez-Salas, L. M. Nucleic acids as therapeutic agents. Curr. Top. Med. Chem. 8, 1379–1404 (2008).
  CAS PubMed Google Scholar
• Dalmay, T. MicroRNAs and cancer. J. Intern. Med. 263, 366–375 (2008).
  CAS PubMed Google Scholar
• Huang, C., Li, M., Chen, C. & Yao, Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin. Ther. Targets. 12, 637–645 (2008).
  CAS PubMed Google Scholar
• Mocellin, S., Costa, R. & Nitti, D. RNA interference: ready to silence cancer? J. Mol. Med. 84, 4–15 (2006).
  CAS PubMed Google Scholar
• Moreira, J. N., Santos, A. & Simoes, S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev. Recent Clin. Trials 1, 217–235 (2006).
  CAS PubMed Google Scholar
• Zheng, X. et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J. Immunol. 177, 5639–5646 (2006).
  CAS PubMed Google Scholar
• Jeong, Y. I. et al. (–)-Epigallocatechin gallate suppresses indoleamine 2,3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem. Biophys. Res. Commun. 354, 1004–1009 (2007).
  CAS PubMed Google Scholar
• Lee, H. J. et al. Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Biochem. Pharmacol. 73, 1412–1421 (2007).
  PubMed Google Scholar
• Kim, S. I. et al. _p_-Coumaric acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Int. Immunopharmacol 7, 805–815 (2007).
  CAS PubMed Google Scholar
• Mehta, R. G. et al. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 16, 399–404 (1995).
  CAS PubMed Google Scholar
• Park, E. J. & Pezzuto, J. M. Botanicals in cancer chemoprevention. Cancer Metastasis Rev. 21, 231–255 (2002).
  CAS PubMed Google Scholar
• Banerjee, T. et al. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27, 2851–2857 (2008).
  CAS PubMed Google Scholar
• Gaspari, P. et al. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem. 49, 684–692 (2006).
  CAS PubMed PubMed Central Google Scholar
• Brastianos, H. C. et al. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J. Am. Chem. Soc. 128, 16046–16047 (2006).
  CAS PubMed Google Scholar
• Carr, G., Chung, M. K., Mauk, A. G. & Andersen, R. J. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J. Med. Chem. 51, 2634–2637 (2008).
  CAS PubMed Google Scholar
• Kumar, S. et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J. Med. Chem. 51, 4968–4977 (2008).
  CAS PubMed PubMed Central Google Scholar
• Pereira, A., Vottero, E., Roberge, M., Mauk, A. G. & Andersen, R. J. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific marine hydroid Garveia annulata. J. Nat. Prod. 69, 1496–1499 (2006).
  CAS PubMed Google Scholar
• Sugimoto, H. et al. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl Acad. Sci. USA 103, 2611–2616 (2006).
  CAS PubMed PubMed Central Google Scholar
• Boasso, A. et al. Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. J. Immunol. 182, 4313–4320 (2009).
  CAS PubMed Google Scholar
• Ogata, S. et al. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 cells. Biosci. Biotechnol. Biochem. 64, 327–332 (2000).
  CAS PubMed Google Scholar
• Braun, D., Longman, R. S. & Albert, M. L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106, 2375–2381 (2005).
  CAS PubMed PubMed Central Google Scholar
• Lopez, A. S., Alegre, E., Diaz, A., Mugueta, C. & Gonzalez, A. Bimodal effect of nitric oxide in the enzymatic activity of indoleamine 2,3-dioxygenase in human monocytic cells. Immunol. Lett. 106, 163–171 (2006).
  CAS PubMed Google Scholar
• Belladonna, M. L. et al. Cutting edge: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 181, 5194–5198 (2008).
  CAS PubMed Google Scholar
• Gura, T. How embryos may avoid immune attack. Science 281, 1122–1124 (1998).
  CAS PubMed Google Scholar
• Kotake, Y. & Masayama, I. The intermediary metabolism of tryptophan XVIII. The mechanism of formation of kynurenine from tryptophan Z. Physiol. Chem. 243, 237–244 (1936).
  CAS Google Scholar
• Thackray, S. J., Mowat, C. G. & Chapman, S. K. Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem. Soc. Trans. 36, 1120–1123 (2008).
  CAS PubMed PubMed Central Google Scholar
• Zhang, Y. et al. Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis. Biochemistry 46, 145–155 (2007).
  CAS PubMed Google Scholar
• Beutelspacher, S. C. et al. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am. J. Transplant 6, 1320–1330 (2006).
  CAS PubMed Google Scholar
• Pantoja, L. G., Miller, R. D., Ramirez, J. A., Molestina, R. E. & Summersgill, J. T. Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2,3-dioxygenase activity. Infect. Immun. 68, 6478–6481 (2000).
  CAS PubMed PubMed Central Google Scholar
• Oberdorfer, C., Adams, O., MacKenzie, C. R., De Groot, C. J. & Daubener, W. Role of IDO activation in anti-microbial defense in human native astrocytes. Adv. Exp. Med. Biol. 527, 15–26 (2003).
  PubMed Google Scholar
• Della Chiesa, M. et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108, 4118–4125 (2006).
  CAS PubMed Google Scholar
• Hwu, P. et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164, 3596–3599 (2000).
  CAS PubMed Google Scholar
• Fallarino, F. et al. Modulation of tryptophan catabolism by regulatory T cells. Nature Immunol. 4, 1206–1212 (2003).
  CAS Google Scholar
• Grohmann, U. et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunol. 3, 1097–1101 (2002).
  CAS Google Scholar
• Grohmann, U. et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nature Med. 13, 579–586 (2007).
  CAS PubMed Google Scholar
• Orabona, C. et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nature Immunol. 5, 1134–1142 (2004).
  CAS Google Scholar
• Fallarino, F. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752–6761 (2006).
  CAS PubMed Google Scholar
• Molano, A., Illarionov, P. A., Besra, G. S., Putterman, C. & Porcelli, S. A. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol. Lett. 117, 81–90 (2008).
  CAS PubMed PubMed Central Google Scholar
• Adikari, S. B., Lian, H., Link, H., Huang, Y. M. & Xiao, B. G. Interferon-γ-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. 138, 230–236 (2004).
  CAS PubMed PubMed Central Google Scholar
• Ino, K. et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer 95, 1555–1561 (2006).
  CAS PubMed PubMed Central Google Scholar
• Takao, M. et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol. Rep. 17, 1333–1339 (2007).
  CAS PubMed Google Scholar